Advertisement

Inflammation pp 201-209 | Cite as

Bacteriophage Therapy of Bacterial Infections: An Update of our Institute’s Experience

  • Beata Weber-Dąbrowska
  • Marian Mulczyk
  • Andrzej Górski
Chapter

Abstract

1307 patients with suppurative bacterial infections caused by multidrug-resistant bacteria of different species were treated with specific bacteriophages (BP). BP therapy was highly effective; full recovery was noted in 1123 cases (85.9%). In 134 cases (10.9%) transient improvement was observed and only in 50 cases (3.8%) was BP treatment found to be ineffective. The results confirm the high effectiveness of BP therapy in combating bacterial infections which do not respond to treatment with the available antibiotics.

Key words

phage therapy drug resistance bacterial infections. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackerman H. W. and Dubow M. (1987): Viruses of prokaryotes. I. General properties of bacteriophages. CRC Press, Boca Roton, Florida.Google Scholar
  2. Barrow R. A. and Soothill J. S. (1997): Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol., 5, 258–271.CrossRefGoogle Scholar
  3. Berchieri A. Jr., Lovell M. A. and Barrow P. A. (1991): The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res. Microbiol., 142, 541–549.PubMedCrossRefGoogle Scholar
  4. Bruynoghe R. and Maisin J. (1921): Essais de therapeutique au moyem du bactériophage. C. R. Soc. Biol., 85, 1120–1121.Google Scholar
  5. Carlton R. M. (1999): Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp., 47, 267–274.Google Scholar
  6. Cislo M., Dabrowski M., Weber-Dabrowska B. and Wojtorí A. (1987): Bacteriophage treatment of suppurative skin infection. Arch. Immunol. Ther. Exp., 35, 175–183.Google Scholar
  7. Cohen M. L. (1992): Epidemiology of drug resistance: implications for a post-antimicrobial era. Science, 257, 1050.PubMedCrossRefGoogle Scholar
  8. Gilmore M. S. and Hoch J. A. (1999): A vancomycine surprise. Nature, 399, 524–527.PubMedCrossRefGoogle Scholar
  9. Holzman D. (1988): Phage as antibacterial tool. Genet. Eng. News, 15 Oct., pp. 1, 12, 41, 48.Google Scholar
  10. Kutter E. (1997): Phage therapy. Bacteriophages as antibiotics. Evergreen State College. Olympia WA 98505 Nov. 15.Google Scholar
  11. Lorch A. (1999): Bacteriophages an alternative to antibiotics. Biotech. Develgo Monitor, 39, 14–17.Google Scholar
  12. Lederberg J. (1996): Commentary. Proc. Acad. Sci. USA, 93, 3167–3168.CrossRefGoogle Scholar
  13. Neu H. C. (1992): The crisis in antibiotic resistance. Science, 257, 1064–1071.PubMedCrossRefGoogle Scholar
  14. Novak R., Henriques B., Charpentier E., Normark S. and Tuomanen E. (1999): Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature, 399, 590–593.PubMedCrossRefGoogle Scholar
  15. Sieradzki K., Roberts R. B., Haber S. W. and Tomasz A. (1999): The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus. N. Engl. J. Med., 340, 517–523.PubMedCrossRefGoogle Scholar
  16. Smith T. L., Pearson M. L., Wilcox K. R., Cruz C., Lancaster M. V., Robinson-Dunn B., Tenover F. C., Zervos M. J., Band J. D., White E. and Jarvis W. R. (1999): Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med., 340, 493–501.PubMedCrossRefGoogle Scholar
  17. Smith H. W. and Huggins R. B. (1983): Effectivenes of phages in treating experimental E. coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol., 129, 2659–2675.PubMedGoogle Scholar
  18. Smith H. W. and Huggins R. B. (1987): The control of experimental E. coli in calves by means of bacteriophage. J. Gen. Microbiol., 133, 1111–1126.PubMedGoogle Scholar
  19. Strój L., Weber-Dabrowska B., Partyka K., Mulczyk M. and Wójcik M. (1999): Successful bacteriophage treatment in purulent cerebrospinal meningitis in a newborn (in Polish). Neur. Neuroch. Pol., 33, 693–698.Google Scholar
  20. Slopek S., Durlakowa I., Weber-Dabrowska B., Kucharewicz-Krukowska A., Dabrowski M. and Bisikiewicz R. (1983a): Results of bacteriophage treatment of suppurative bacterial infections. I. General evolution of the results. Arch. Immunol. Ther. Exp., 31, 267–291.Google Scholar
  21. lopek S., Durlakowa I., Weber-Dabrowska B., Kucharewicz-Krukowska A., Dabrowski M. and Bisikiewicz R. (1983b): Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch. Immunol. Ther. Exp., 31, 293–327.Google Scholar
  22. lopek S., Durlakowa I., Weber-Dqbrowska B. and Kucharewicz-Krukowska A. (1984): Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch. Immunol. Ther. Exp., 32, 317–335.Google Scholar
  23. lopek S., Kucharewicz-Krukowska A., Weber-Dqbrowska B. and Dqbrowski M. (1985a): Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch. Immunol. Ther. Exp., 33, 219–240.Google Scholar
  24. lopek S., Kucharewicz-Krukowska A., Weber-Dgbrowska B. and Dqbrowski M. (1985b): Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch. Immunol. Ther. Exp., 33, 241–260.Google Scholar
  25. lopek S., Kucharewicz-Krukowska A., Weber-Dqbrowska B. and Dqbrowski M. (1985c): Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative Staphylococcus infections. Arch. Immunol. Ther. Exp., 33, 261–273.Google Scholar
  26. lopek S., Weber-Dbrowska B., Dqbrowski M. and Kucharewicz-Krukowska A. (1987): Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch. Immunol. Ther. Exp., 35, 569–583.Google Scholar
  27. Valdvogel F. (1999): New resistance in Staphylococcus aureus. N. Engl. J. Med., 340, 556–557.CrossRefGoogle Scholar
  28. Vieu J. F. (1975): Les Bacteriophages. In Fabre J. (ed.): Fraite de Therapeutique, Vol. Serums et Vaccins. Flammarion, Paris, 337–400.Google Scholar
  29. Vieu J. F. et al. (1979): Donnees actueles sur les applications therapeutiques des bacteriophages. Bull. Natl. Med., 103–161.Google Scholar
  30. Weber-Dabrowska B., Kozmiríska J., Mulczyk M. and Kaczkowski H. (1996): The use of bacteriophages in the treatment of chronic suppurative sinusitis (in Polish). Post. Med. Klin. Dogw., 5, 291–293.Google Scholar
  31. Weber-Dabrowska B., Mulczyk M. and Górski A. (2001): Therapy of infections in cancer patients with bacteriophages. Clin. Appl. Immunol. Rev., 1, 1–4.CrossRefGoogle Scholar
  32. Weber-Dabrowska B., Zimecki M. and Mulczyk M. (2000): Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp., 48, 31–37.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Beata Weber-Dąbrowska
    • 1
  • Marian Mulczyk
    • 1
  • Andrzej Górski
    • 1
  1. 1.Laboratory of Bacteriophages, Institute of Immunology and Experimental TherapyPolish Academy of SciencesWrocławPoland

Personalised recommendations